Skip Navigation LinksHome > September 2014 - Volume 33 - Issue 9 > Single-dose Pharmacokinetics of Daptomycin in Pediatric Pati...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0000000000000318
Antimicrobial Reports

Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3–24 Months of Age

Bradley, John S. MD*; Benziger, David PhD; Bokesch, Paula MD; Jacobs, Richard MD

Supplemental Author Material
Collapse Box


Background: Daptomycin is approved for treatment of complicated skin/skin structure infections and Staphylococcus aureus bloodstream infections (bacteremia) in adults. This study was undertaken to determine the pharmacokinetics of daptomycin in pediatric patients 3–24 months of age with proven/suspected bacterial infection.

Methods: In this phase 1, multicenter, open-label, noncomparative pharmacokinetic and safety study, patients were enrolled in 3 age groups: 3–6, 7–12 and 13–24 months. Intravenous daptomycin (single dose) was infused over 30 minutes at 6 mg/kg in subjects 13–24 months of age and at 4 mg/kg in the younger groups. Blood was collected for analysis of daptomycin concentrations.

Results: Twenty-four subjects received daptomycin. Daptomycin exposures (area under the curve0–∞) in children 3–6 and 7–12 months of age receiving 4 mg/kg were similar (215 and 219 μg·h/mL, respectively). Children 13–24 months of age receiving a higher dose, 6 mg/kg, had higher exposures (282 μg·h/mL). Mean maximum plasma concentrations in the age groups were 38.7, 37.1 and 67.0 μg/mL, respectively. Daptomycin exposures based on mg/kg dosing were lower than previously reported for older children and adults, likely because of increased clearance and volume of distribution and decreased apparent elimination half-life. Single-dose daptomycin 4 and 6 mg/kg was well tolerated and was not associated with clinical or laboratory adverse events.

Conclusions: To match known clinically and microbiologically effective exposures in adults, infants require higher mg/kg daptomycin doses. Daptomycin safety and efficacy have not been established in pediatric patients. Pediatric clinical trials are ongoing.

© 2014 by Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.